Characteristics and Outcomes of Hepatocellular Carcinoma (HCC) in Patients with Autoimmune Hepatitis (AIH): Insights from the Italian Liver Cancer (ITA.LI.CA) Database

IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
{"title":"Characteristics and Outcomes of Hepatocellular Carcinoma (HCC) in Patients with Autoimmune Hepatitis (AIH): Insights from the Italian Liver Cancer (ITA.LI.CA) Database","authors":"","doi":"10.1016/j.dld.2024.08.022","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The incidence of HCC in patients with autoimmune hepatitis AIH patients is low (0.09% per year), with higher risk in those with additional risk factors.</p></div><div><h3>Aim</h3><p>To report characteristics and outcomes of patients with AIH and HCC.</p></div><div><h3>Materials and Methods</h3><p>We analyzed data from the ITA.LI.CA database (2009-2022) including 8,038 HCC and identified 18 patients (0.2%) with AIH and HCC. We evaluated liver disease-related characteristics, modality of HCC diagnosis, tumor stage, treatment, recurrence, overall survival (OS), and causes of death.</p></div><div><h3>Results</h3><p>Median age was 67.2 years, and male patients represented 50.0% of cases. Most patients had cirrhosis (90%). Two patients (11.1%) had Primary Biliary Cholangitis overlap, three (16.7%) concomitant alcohol abuse, while 4 (22.2%) and 3 (16.7%) were overweight and obese, respectively. Median MELD score was 11 (IQR 9-13). HCC diagnosis occurred primary during surveillance (55.6%). Most patients had single tumour (77.8%), median HCC diameter was 2.8cm (1.5–3.2), three patients (16.7%) had extra-hepatic spread or macro-vascular invasion, and 72.2% were Milan-in. Treatment with curative intent was performed in 11 patients (33.3% ablation, 22.2% resection, 5.5% transplantation). Trans-arterial chemoembolization was carried out in 6 patients (33.3%), and one patient (5.5%) was managed with best supportive care. Objective response was observed in 66.7% of patients, and early recurrence occurred in 2 patients (11.8%). Median OS was 41.7 months, and main causes of death were end-stage liver disease (57.1%) and HCC progression (42.9%). OS was longer in patients under surveillance than in those diagnosed incidentally or due to symptoms (27.3 <em>vs.</em> 62.8 months, p=0.049).</p></div><div><h3>Conclusions</h3><p>HCC in AIH is a rare event, occurring prevalently in older, male patients with cirrhosis, and with frequent concurrent factors for HCC occurrence. A high surveillance rate is associated with favorable staging at diagnosis, and with access to potentially curative treatments, thus resulting in improved survival.</p></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1590865824009411","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The incidence of HCC in patients with autoimmune hepatitis AIH patients is low (0.09% per year), with higher risk in those with additional risk factors.

Aim

To report characteristics and outcomes of patients with AIH and HCC.

Materials and Methods

We analyzed data from the ITA.LI.CA database (2009-2022) including 8,038 HCC and identified 18 patients (0.2%) with AIH and HCC. We evaluated liver disease-related characteristics, modality of HCC diagnosis, tumor stage, treatment, recurrence, overall survival (OS), and causes of death.

Results

Median age was 67.2 years, and male patients represented 50.0% of cases. Most patients had cirrhosis (90%). Two patients (11.1%) had Primary Biliary Cholangitis overlap, three (16.7%) concomitant alcohol abuse, while 4 (22.2%) and 3 (16.7%) were overweight and obese, respectively. Median MELD score was 11 (IQR 9-13). HCC diagnosis occurred primary during surveillance (55.6%). Most patients had single tumour (77.8%), median HCC diameter was 2.8cm (1.5–3.2), three patients (16.7%) had extra-hepatic spread or macro-vascular invasion, and 72.2% were Milan-in. Treatment with curative intent was performed in 11 patients (33.3% ablation, 22.2% resection, 5.5% transplantation). Trans-arterial chemoembolization was carried out in 6 patients (33.3%), and one patient (5.5%) was managed with best supportive care. Objective response was observed in 66.7% of patients, and early recurrence occurred in 2 patients (11.8%). Median OS was 41.7 months, and main causes of death were end-stage liver disease (57.1%) and HCC progression (42.9%). OS was longer in patients under surveillance than in those diagnosed incidentally or due to symptoms (27.3 vs. 62.8 months, p=0.049).

Conclusions

HCC in AIH is a rare event, occurring prevalently in older, male patients with cirrhosis, and with frequent concurrent factors for HCC occurrence. A high surveillance rate is associated with favorable staging at diagnosis, and with access to potentially curative treatments, thus resulting in improved survival.

自身免疫性肝炎 (AIH) 患者肝细胞癌 (HCC) 的特征和预后:来自意大利肝癌(ITA.LI.CA)数据库的启示
导言自身免疫性肝炎AIH患者的HCC发病率较低(每年0.09%),具有其他风险因素的患者发病风险更高。我们评估了肝病相关特征、HCC 诊断方式、肿瘤分期、治疗、复发、总生存期(OS)和死亡原因。结果中位年龄为 67.2 岁,男性患者占 50.0%。大多数患者患有肝硬化(90%)。两名患者(11.1%)合并原发性胆管胆管炎,三名患者(16.7%)同时酗酒,四名患者(22.2%)超重,三名患者(16.7%)肥胖。MELD 评分中位数为 11(IQR 9-13)。HCC 诊断主要发生在监测期间(55.6%)。大多数患者为单发肿瘤(77.8%),HCC直径中位数为2.8厘米(1.5-3.2),3名患者(16.7%)有肝外扩散或大血管侵犯,72.2%为米兰入院。11名患者接受了根治性治疗(33.3%消融,22.2%切除,5.5%移植)。6名患者(33.3%)接受了经动脉化疗栓塞,1名患者(5.5%)接受了最佳支持治疗。66.7%的患者出现了客观反应,2名患者(11.8%)出现了早期复发。中位生存期为41.7个月,主要死因是终末期肝病(57.1%)和HCC进展(42.9%)。结论 AIH 中的 HCC 比较罕见,主要发生在年龄较大、患有肝硬化的男性患者中,而且 HCC 的发生有很多并发因素。高监测率与诊断时的良好分期和潜在的根治性治疗相关,从而提高了生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Digestive and Liver Disease
Digestive and Liver Disease 医学-胃肠肝病学
CiteScore
6.10
自引率
2.20%
发文量
632
审稿时长
19 days
期刊介绍: Digestive and Liver Disease is an international journal of Gastroenterology and Hepatology. It is the official journal of Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Pancreas (AISP); Italian Association for Digestive Endoscopy (SIED); Italian Association for Hospital Gastroenterologists and Digestive Endoscopists (AIGO); Italian Society of Gastroenterology (SIGE); Italian Society of Pediatric Gastroenterology and Hepatology (SIGENP) and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease publishes papers on basic and clinical research in the field of gastroenterology and hepatology. Contributions consist of: Original Papers Correspondence to the Editor Editorials, Reviews and Special Articles Progress Reports Image of the Month Congress Proceedings Symposia and Mini-symposia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信